Bosch and Randox Laboratories Ltd. Announce Strategic Partnership for Vivalytic Analysis Platform
On Wednesday 10 April, 2024, Bosch, a leading technology company, and Randox Laboratories Ltd., a prominent diagnostic and medical technology company, announced a strategic partnership. The two companies will jointly invest around 150 million euros in research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare.
One of the main goals of this partnership is to develop a highly innovative and novel BioMEMS technology-based sepsis IVD grade test. This test will be the first of its kind and is expected to have a significant impact on the healthcare industry.
According to Marc Meier, managing director of Bosch Healthcare Solutions GmbH, this partnership is a step towards the trend of decentralized and personalized diagnostics. “Globally, healthcare is moving towards decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,” Meier says. “With our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular-diagnostic PCR tests provide clarity directly at the site of sample collection, shorten waiting times, and take the strain off the healthcare system.”
The development partnership with Randox will focus on implementing a highly sensitive multiplex test for sepsis on the Vivalytic analysis platform. Sepsis is a life-threatening complication that can occur with various infectious diseases and requires immediate medical treatment. Dr. Peter Fitzgerald, Managing Director of Randox Laboratories Ltd., emphasizes the importance of early diagnosis and treatment for sepsis. “Clinical outcomes in sepsis depend on timely diagnosis and appropriate early therapeutic intervention,” Fitzgerald says. “Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using a highly multiplexing BioMEMS chip. Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition.”
The BioMEMS chip, which combines microelectromechanical systems (MEMS) with microfluidics, will be able to test for more than 250 genetic characteristics in less than 15 minutes. This revolutionary technology will allow for the simultaneous testing of various pathogens, drug resistance, and genetic mutations in tumors. It also has the potential to be used in oncology in the future.
In addition, the BioMEMS technology will enable easier and faster adaptation of new tests or existing tests on the chip itself. “Our test cartridge is a highly complex laboratory the size of a smartphone, so to speak,” Meier explains. “This will enable fully automatic testing of up to 250 genetic characteristics in one cartridge and in some instances in less than 15 minutes.”
For press inquiries, please contact Thomas Berroth, Marketing & Communication, at Thomas.berroth2@de.bosch.com or +49 (0) 160 90437856.
###
About Bosch
Bosch is a leading global supplier of technology and services. Its operations are divided into four business sectors: Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology. As a leading provider of smart solutions, Bosch is committed to creating a sustainable future through innovative technologies that improve quality of life. In the healthcare sector, Bosch is dedicated to developing molecular diagnostics solutions to support decentralized and personalized diagnostics.
About Randox Laboratories Ltd.
Randox Laboratories Ltd. is a leading diagnostic and medical technology company, headquartered in Northern Ireland. With over 10 years of experience in the field of infectious diseases diagnostics, Randox is committed to developing and delivering innovative solutions to improve healthcare outcomes. The company’s goal is to revolutionize sepsis diagnosis with the development of a highly multiplexing BioMEMS chip. This technology has the potential to significantly improve treatment outcomes and reduce mortality rates from this life-threatening condition.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.